Skip to main content
. 2012 Mar 20;20(7):1338–1348. doi: 10.1038/mt.2012.12

Figure 1.

Figure 1

Efficacy and astrocyte specificity of shAct1 lentiviral vector. (a) Schematic map of the astrocyte-specific shAct1 lentiviral vector. (b) Primary astrocytes were infected with shAct1- and control lentivirus. Three days later, Act1 mRNA expression was assayed by real-time RT-PCR. **P < 0.01 (n = 3 each group). (c) Act1 protein expression (red) in astrocytes (green) was determined by immunohistochemistry. (d) Act1 protein expression in astrocytes was determined by western blot. (e) Immunofluorescence of GFP (green) and neural specific markers (red) in spinal cord tissue sections 3 days after i.c.v. injection. GFAP, astrocytes; NeuN, neurons; GalC, oligodendrocytes; CD11b, microglia; NG2, oligodendrocyte progenitor cells (OPCs). GFAP, glial fibrillary acidic protein; i.c.v., intracerebroventricular; LTR, long terminal repeat; mRNA, messenger RNA; RT-PCR, reverse transcription-PCR.